Last reviewed · How we verify

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia — Portfolio Competitive Intelligence Brief

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia pipeline: 1 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Cabotegravir LA + Rilpivirine LA Cabotegravir LA + Rilpivirine LA marketed Antiretroviral combination (INSTI + NNRTI) HIV integrase and HIV reverse transcriptase Infectious Disease / Virology
Hipec with Cisplatin Hipec with Cisplatin phase 3 Regional chemotherapy / Intraperitoneal chemotherapy DNA (cisplatin acts as a platinum-based alkylating agent) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Dong-A ST Co., Ltd. · 1 shared drug class
  2. Generic (originally Searle/Pfizer) · 1 shared drug class
  3. Shanghai 10th People's Hospital · 1 shared drug class
  4. University Paris 7 - Denis Diderot · 1 shared drug class
  5. West China Hospital · 1 shared drug class
  6. Wolfson Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia:

Cite this brief

Drug Landscape (2026). Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundacion-para-la-formacion-e-investigacion-sanitarias-de-la-region-de-murcia. Accessed 2026-05-17.

Related